We have recently showed that a selective MEK inhibitor encapsulated in P-selectin-targeted nanoparticles exhibited improved efficacy over the free drug with lower dosing and prolonged target engagement in the tumour compared with the skin, a major site of on-target toxicity20. Here, SELP is linked to neoplasm.